Business Description
Fate Therapeutics Inc
NAICS : 325412
SIC : 2836
ISIN : US31189P1021
Total Employee Number:
161Compare
Compare
Traded in other countries / regions
FATE.USAF6T.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2013-10-01Description
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.28 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.43 | |||||
Debt-to-EBITDA | -0.61 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -7.16 | |||||
Beneish M-Score | -4.17 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -61.7 | |||||
3-Year EBITDA Growth Rate | 28 | |||||
3-Year EPS without NRI Growth Rate | 28.3 | |||||
3-Year FCF Growth Rate | 31.5 | |||||
3-Year Book Growth Rate | -28.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 2.42 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -11.8 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.12 | |||||
9-Day RSI | 51.9 | |||||
14-Day RSI | 51.73 | |||||
3-1 Month Momentum % | 74.8 | |||||
6-1 Month Momentum % | 115 | |||||
12-1 Month Momentum % | 95.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.85 | |||||
Quick Ratio | 5.85 | |||||
Cash Ratio | 5.7 | |||||
Days Sales Outstanding | 70.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.8 | |||||
Shareholder Yield % | 5.42 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2207.47 | |||||
Net Margin % | -2056.79 | |||||
EBITDA Margin % | -2009.79 | |||||
FCF Margin % | -1711.42 | |||||
OCF Margin % | -1632.31 | |||||
ROE % | -55.48 | |||||
ROA % | -37.81 | |||||
ROIC % | -102.95 | |||||
3-Year ROIIC % | -121.99 | |||||
ROC (Joel Greenblatt) % | -137.06 | |||||
ROCE % | -44.51 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 39.53 | |||||
PB Ratio | 1.36 | |||||
Price-to-Tangible-Book | 1.36 | |||||
EV-to-EBIT | -1.05 | |||||
EV-to-EBITDA | -1.15 | |||||
EV-to-Revenue | 23.14 | |||||
EV-to-Forward-Revenue | 25.2 | |||||
EV-to-FCF | -1.35 | |||||
Price-to-GF-Value | 3.74 | |||||
Price-to-Median-PS-Value | 1.01 | |||||
| Price-to-Net-Current-Asset-Value | 3.28 | |||||
| Price-to-Net-Cash | 3.49 | |||||
Earnings Yield (Greenblatt) % | -95.24 | |||||
FCF Yield % | -44.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FATE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fate Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.316 | ||
| EPS (TTM) ($) | -1.09 | ||
| Beta | 3.6979 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 0.65 | ||
| Volatility % | 135.9 | ||
| 14-Day RSI | 51.73 | ||
| 14-Day ATR ($) | 0.232523 | ||
| 20-Day SMA ($) | 2.12825 | ||
| 12-1 Month Momentum % | 95.45 | ||
| 52-Week Range ($) | 0.91 - 2.88 | ||
| Shares Outstanding (Mil) | 116.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fate Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fate Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 138 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 45 days | ||
| General meeting for 2026 | 2026-06-12 09:30 | 1.97 (+2.60%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 2.25 (+2.74%) | ||
| Guidance call for 2026 | 2026-03-09 09:20 | 1.33 (-0.75%) | ||
| Annual report for 2025 | 2026-02-26 | 1.48 (-8.64%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 1.48 (-8.64%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 1.04 (-6.31%) | ||
| Guidance call for 2025 | 2025-09-04 10:55 | 1.00 (-2.91%) | ||
| Guidance call for 2025 | 2025-09-03 | 1.03 (-0.96%) |
Show
Entries
Fate Therapeutics Inc Frequently Asked Questions
What is Fate Therapeutics Inc(FATE)'s stock price today?
The current price of FATE is $2.10. The 52 week high of FATE is $2.88 and 52 week low is $0.91.
When is next earnings date of Fate Therapeutics Inc(FATE)?
The next earnings date of Fate Therapeutics Inc(FATE) is 2026-08-12 Est..
Does Fate Therapeutics Inc(FATE) pay dividends? If so, how much?
Fate Therapeutics Inc(FATE) does not pay dividend.
Guru Commentaries on NAS:FATE
No articles.
Press Release
Articles on Fate Therapeutics Inc
No articles.
Headlines
See More- 1
Jun 15, 2026
Fate Therapeutics Appoints Laura Hamill to Board of Directors
Benzinga • 7:30am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers